AEON Biopharma, Inc.
AEON
Analytical Summary
On an absolute basis, AEON Biopharma, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.
5-Year Financial Trajectory
Annualinfo Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.
Bullish Indicators
- No bullish signals detected.
Bearish Risks
- FCF / Net IncomeFCF / Net Income of 0.44x is weak on an absolute basis (target > 1x)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2022 10-K ↗ | FY 2022 Dec 31, 2021 10-K ↗ | FY 2021 Dec 31, 2020 10-K ↗ |
|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
→
Excellent
Stable
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| FCF / Net Income (x) |
0.44x
Weak
↑
Weak
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.48x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.68x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.18x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2022 10-K ↗ | FY 2022 Dec 31, 2021 10-K ↗ | FY 2021 Dec 31, 2020 10-K ↗ |
|---|---|---|---|---|---|
| Return on Invested Capital (%) | — | — |
16.8%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
9.0%
Fair
Fair
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-230.3%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
2322.9%
Excellent
↑
Excellent
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-449.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-0.7%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) | — | — |
18.3%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+22%)
|
-48.4%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-423%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2022 10-K ↗ | FY 2022 Dec 31, 2021 10-K ↗ | FY 2021 Dec 31, 2020 10-K ↗ |
|---|---|---|---|---|---|
| Depreciation Expense (USD) | $78.00K | $97.00K | $68.00K | — | — |
| Net Income, GAAP (USD) | $-39.22M | $42.01M | $-52.56M | $8.20M | — |
| Operating Cash Flow (USD) | $-17.31M | $-20.29M | $-35.58M | $-1.49M | — |
Secondary lens
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Unavailable
Benchmark Lens
Benchmarks are disabled until comparison data is defensible.
Benchmarks unavailable
Verdicts use absolute quality thresholds, not peer comparison — only 0 comparable companies are currently available for ranking.
Use Statement Evidence firstCompare AEON with peers
Stack AEON against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 5 years · 20 quarters